Macomics, cancer therapies spinout, raises £3.2m

Cancer therapies company Macomics, a spin out from the University of Edinburgh, has launched by raising £3.2 million in a seed funding round led by Epidarex Capital and supported by the Scottish Investment Bank.

Company formation and in-licensing of the technology was facilitated by Edinburgh Innovations, the commercialisation service for the University of Edinburgh.

Macomics said it will use the proceeds of this fundraising round to “develop novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours.”

Macomics’ approach is based on academic research around macrophage biology, particularly in cancer, from the laboratory of Professor Jeffrey Pollard, Director of the MRC Centre for Reproductive Health at the University of Edinburgh, working with co-founder Dr Luca Cassetta.

In parallel with the financing, Macomics has appointed biotechnology industry experts Dr Robert Haigh and Dr Jane Dancer as CEO and non-executive director respectively.

Haigh has worked extensively in R&D in the pharmaceutical and biotechnology industry, with roles at Ferring and Boehringer Ingelheim, where he was involved in oncology research.

Dancer is a business development expert with over 30 years’ experience in the life science industry across biotech, pharma and agrochemicals. She was formerly chief business officer at F-star, VP Business Development at Cellzome and Director, Business Development at Cambridge Antibody Technology Ltd.

Elizabeth Roper, partner at Epidarex Capital and investor director at Macomics, said: “We have known Jeff and his team and followed their world-leading research in macrophage biology for some time and are delighted to be leading this investment that triggers the launch of Macomics.

“This is one of the first investments from our new Epidarex Capital III UK fund that was announced recently.

“Despite the good progress that immunotherapies have brought to the treatment of cancer, addressing the hostile tumour environment remains a major obstacle to achieving better clinical outcomes in a broader patient population.

“The macrophage-based approach that Macomics is pioneering has significant potential in the treatment of cancer, as recent deals in the tumour-associated macrophage area indicate.

“We look forward to working with the team to support Macomics’ growth and to help it realise the potential of its world-class science.”

About the Author

Mark McSherry
Dalriada Media LLC sites are edited by veteran news journalist Mark McSherry, a former staff editor and reporter with Reuters, Bloomberg and major newspapers including the South China Morning Post, London's Sunday Times and The Scotsman. McSherry's journalism has also appeared in The Washington Post, The Guardian, The Independent, The New York Times, London's Evening Standard and Forbes. McSherry is also a professor of journalism and communication arts in universities and colleges in New York City. Scottish-born McSherry has an MBA from the University of Edinburgh and a Certificate in Global Affairs from New York University.